Concepedia

David M. Briere

DM

21

Publications

4.3K

Citations

16

H-Index

2010

Active since

Affiliations

Mirati Therapeutics (United States)(Current)

Pfizer (United States)

Array BioPharma (United States)

Pfizer (United Kingdom)

The University of Texas MD Anderson Cancer Center

David M. Briere is an author at Mirati Therapeutics (United States) specializing in medicine, tumor biology, and cell biology.

ORCID

Top concepts

Publications per year

2010–2025

21

Publications

21

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.2K citations · Full text

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 644 citations · Full text

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 559 citations · Full text

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

, , +7

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 163 citations · Full text

Rows per page

1–5 of 21